Sunday, November 3, 2024
Facebook Linkedin Twitter
HomeTagsOral PD-L1

Oral PD-L1

Biotechnology

Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1

PR Newswire -
Ascletis Pharma Inc. announces the completion of first patient dosing in the U.S. Phase I clinical trial of ASC61, an oral PD-L1 small molecule...
Biotechnology

Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors

PR Newswire -
Ascletis Pharma Inc.  announces the approval of the Investigational New Drug (IND) application by U.S. Food and Drug Administration (FDA) for in-house developed oral...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us